Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial - Christopher C. Butler, Najib M. Rahman, Duncan B. Richards, Joseph F. Standing, Benjamin R. Saville, Heather Rutter, Nicholas P. B. Thomas, May Ee Png, Oliver van Hecke, Christina T. Saunders, Ivy Raymundo-Wood, Andrew Ustianowski, Ly-Mee Yu, Nigel de Kare-Silver, Satveer Poonian - Dissemin

Dissemin is shutting down on January 1st, 2025

Language
Login

Published in

Elsevier, The Lancet, 10373(401), p. 281-293, 2023

DOI: 10.1016/s0140-6736(22)02597-1

Links

Tools

Export citation

Search in Google Scholar

Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial

Journal article published in 2023 by Christopher C. Butler, Najib M. Rahman, Duncan B. Richards, Joseph F. Standing, Benjamin R. Saville, Heather Rutter, Nicholas P. B. Thomas, May Ee Png, Oliver van Hecke, Christina T. Saunders, Ivy Raymundo-Wood, Andrew Ustianowski, Ly-Mee Yu, Nigel de Kare-Silver, Satveer Poonian and other authors.

This paper was not found in any repository, but could be made available legally by the author.

This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle

Preprint: archiving allowed

Upload

Green circle

Postprint: archiving allowed

Upload

Red circle

Published version: archiving forbidden

Policy details

Data provided by

SHERPA/RoMEO